Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia
Authors:
- 25 November 2023
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 64, 101156
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaLeukemia, 2019
- NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyBlood Advances, 2019
- NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemiaAmerican Journal of Hematology, 2019
- Patterns of mutations in TP53 mutated AMLBest Practice & Research Clinical Haematology, 2018
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood, 2017
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood, 2015
- Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type ChemotherapyBlood, 1997
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976